Summary of 2021 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-infected Koreans

키워드

참고문헌 (90)

1. The Korean Society for AIDS, "The 2018 Clinical Guidelines for the Diagnosis and Treatment of HIV", AIDS in HIV-Infected Koreans, 2019, pp.51(1), 77~88[DOI]
2. "Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV"[URL]
3. Mellors JW, "Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1infection", Ann Intern Med, 126, pp.946~954 (1997)
4. "European AIDS Clinical Society (EACS) Guidelines for the management of people living with HIV (PLWH) in Europe"[URL]
5. Freedberg KA, "Initial assessment of patients infected with human immunodeficiency virus: the yield and cost of laboratory testing", J Acquir Immune Defic Syndr, 7, pp.1134~1140 (1994)
6. "uidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV"[URL]
7. Brogly SB, "Reproductive health of adolescent girls perinatally infected with HIV", Am J Public Health, 97, pp.1047~1052 (2007)
8. "Recommendations for HIV prevention with adults and adolescents with HIV in the United States, 2014"[URL]
9. Girard PM, "Can we stop CD4+ testing in patients with HIV-1 RNA suppression on antiretroviral treatment?", AIDS, 27, pp.2759~2763 (2013)
10. Anonymous, "Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: a meta-analysis", AIDS Res Hum Retroviruses, 16, pp.1123~1133 (2000)
11. Lucas GM, "Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America", Clin Infect Dis, 59, pp.e96~e138 (2014)
12. Aberg JA, "Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America", Clin Infect Dis, 49, pp.651~681 (2009)
13. Kaplan JE, "Guidelines for preventing opportunistic infections among HIV-infected persons--2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America", MMWR Recomm Rep, 51, pp.1~52 (2002)
14. Hogg RS, "Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy", JAMA, 286, pp.2568~2577 (2001)
15. Mocroft A, "Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group", Lancet, 352, pp.1725~1730 (1998)
16. Palella FJ Jr, "Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata", Ann Intern Med, 138, pp.620~626 (2003)
17. When To Start Consortium. Sterne JA, "Timing of initiation of antiretroviral therapy in AIDSfree HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies", Lancet, 373, pp.1352~1363 (2009)
18. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, "Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study", J Infect Dis, 197, pp.1133~1144 (2008)
19. Cohen MS, "Prevention of HIV-1 infection with early antiretroviral therapy", N Engl J Med, 365, pp.493~505 (2011)
20. Labhardt ND, "Effect of offering same-day ART vs usual health facility referral during home-based HIV testing on linkage to care and viral suppression among adults with HIV in Lesotho: The CASCADE randomized clinical trial", JAMA, 319, pp.1103~1112 (2018)
21. Coffey S, "RAPID antiretroviral therapy: high virologic suppression rates with immediate antiretroviral therapy initiation in a vulnerable urban clinic population", AIDS, 33, pp.825~832 (2019)
22. Török ME, "Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis", Clin Infect Dis, 52, pp.1374~1383 (2011)
23. Boulware DR, "Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis", N Engl J Med, 370, pp.2487~2498 (2014)
24. Molina JM, "Once-daily dolutegravir is superior to once-daily darunavir", ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO, 2014, pp.17(4 Suppl 3), 19490~
25. Raffi F, "Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial", Lancet Infect Dis, 13, pp.927~935 (2013)
26. Gallant J, "Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial", Lancet, 390, pp.2063~2072 (2017)
27. Stellbrink HJ, "Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial", Lancet HIV, 6, pp.e364~e372 (2019)
28. Wohl DA, "Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial", Lancet HIV, 6, pp.e355~e363 (2019)
29. Rockstroh JK, "Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir", emtricitabine in treatment-naive HIV1-infected patients: final 5-year results from STARTMRK, 2013, pp.63, 77~85
30. Cahn P, "Raltegravir 1200 mgonce daily vs 400 mg twice daily, with emtricitabine and tenofovir disoproxil fumarate, for previously untreated HIV-1 infection: Week 96 results from ONCEMRK, a randomized, double-blind, noninferiority trial", J Acquir Immune Defic Syndr, 78, pp.589~598 (2018)
31. Cahn P, "Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials", J Acquir Immune Defic Syndr, 83, pp.310~318 (2020)
32. Orkin C, "Final 192-week efficacy and safety of once-daily darunavir", ritonavir compared with lopinavir, HIV Med, pp.2013, 14[DOI]
33. Orkin C, "Week 96 results of a phase 3 trial of darunavir", cobicistat, tenofovir alafenamide in treatment-naive HIV-1 patients, pp.AIDS, 2020[DOI]
34. Wohl DA, "A randomized, double-blind comparison of single-tablet regimen elvitegravir", cobicistat, tenofovir DF versus single-tablet regimen efavirenz, pp.emtricitabine, tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144results[DOI]
35. Clumeck N, "A randomized, double-blind comparison of singletablet regimen elvitegravir", cobicistat, tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine, pp.tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results, J Acquir Immune Defic Syndr[DOI]
36. Molina JM, "Once-daily atazanavir", ritonavir compared with twice-daily lopinavir, J Acquir Immune Defic Syndr, pp.2010, 53[DOI]
37. Gallant JE, "Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine", tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results, 2013, pp.208, 32~39
38. Molina JM, "Once-daily dolutegravir versus darunavir plus ritonavir for treatmentnaive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study", Lancet HIV, 2, pp.e127~e136 (2015)
39. Daar ES, "Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1", Ann Intern Med, 154, pp.445~456 (2011)
40. van Lunzen J, "Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study", AIDS, 30, pp.251~259 (2016)
41. Palella FJ Jr, "The association of HIV susceptibility testing with survival among HIVinfected patients receiving antiretroviral therapy: a cohort study", Ann Intern Med, 151, pp.73~84 (2009)
42. Cahn P, "Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study", Lancet, 382, pp.700~708 (2013)
43. Eron JJ, "Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials", Lancet Infect Dis, 13, pp.587~596 (2013)
44. Lawrence J, "Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus", N Engl J Med, 349, pp.837~846 (2003)
45. Deeks SG, "Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia", N Engl J Med, 344, pp.472~480 (2001)
46. Ledergerber B, "Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes", Lancet, 364, pp.51~62 (2004)
47. Dinoso JB, "Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy", Proc Natl Acad Sci U S A, 106, pp.9403~9408 (2009)
48. INSIGHT-ESPRIT Study Group, "Interleukin-2 therapy in patients with HIV infection", N Engl J Med, 361, pp.1548~1559 (2009)
49. Peters MG, "Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127", Hepatology, 44, pp.1110~1116 (2006)
50. de Vries-Sluijs TE, "Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus", Gastroenterology, 139, pp.1934~1941 (2010)
51. Matthews GV, "Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV", HBV coinfected individuals, 2009, pp.23, 1707~1715
52. McMahon MA, "The HBV drug entecavir - effects on HIV-1 replication and resistance", N Engl J Med, 356, pp.2614~2621 (2007)
53. Dore GJ, "Frequent hepatitis B virus rebound among HIVhepatitis B virus-coinfected patients following antiretroviral therapy interruption", AIDS, 24, pp.857~865 (2010)
54. Macías J, "Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus", hepatitis C virus, 2009, pp.50, 1056~1063
55. Ragni MV, "Highly active antiretroviral therapy improves ESLD-free survival in HIV-HCV co-infection", Haemophilia, 15, pp.552~558 (2009)
56. Bersoff-Matcha SJ, "Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: a review of cases reported to the U.S. Food and Drug Administration adverse event reporting system", Ann Intern Med, 166, pp.792~798 (2017)
57. Wang C, "Hepatitis due to Reactivation of Hepatitis B Virus in Endemic Areas Among Patients With Hepatitis C Treated With Direct-acting Antiviral Agents", Clin Gastroenterol Hepatol, 15, pp.132~1326.F (2017)
58. Blanc FX, "Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis", N Engl J Med, 365, pp.1471~1481 (2011)
59. Havlir DV, "Timing of antiretroviral therapy for HIV-1infection and tuberculosis", N Engl J Med, 365, pp.1482~1491 (2011)
60. Abdool Karim SS, "Integration of antiretroviral therapy with tuberculosis treatment", N Engl J Med, 365, pp.1492~1501 (2011)
61. Mfinanga SG, "Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebocontrolled trial", Lancet Infect Dis, 14, pp.563~571 (2014)
62. Little SJ, "Antiretroviral-drug resistance among patients recently infected with HIV", N Engl J Med, 347, pp.385~394 (2002)
63. Borroto-Esoda K, "Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz", AIDS Res Hum Retroviruses, 23, pp.988~995 (2007)
64. Pozniak AL, "Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine", lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis, 2006, pp.43, 535~540
65. Kuritzkes DR, "Preexisting resistance to nonnucleoside reversetranscriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects", J Infect Dis, 197, pp.867~870 (2008)
66. Smith DM, "HIV drug resistance acquired through superinfection", AIDS, 19, pp.1251~1256 (2005)
67. Verhofstede C, "Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype", AIDS, 13, pp.2541~2546 (1999)
68. Miller V, "Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure", AIDS, 14, pp.2857~2867 (2000)
69. Devereux HL, "Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy", AIDS, 13, pp.F123~F127 (1999)
70. Anonymous, "ACOG committee opinion no. 762: Prepregnancy counseling", Obstet Gynecol, 133, pp.e78~e89 (2019)
71. Salters K, "Pregnancy incidence and intention after HIV diagnosis among women living with HIV in Canada", PLoS One, 12, pp.e0180524~ (2017)
72. Aebi-Popp K, "Neglect of attention to reproductive health in women with HIV infection: contraceptive use and unintended pregnancies in the Swiss HIV Cohort Study", HIV Med, 19, pp.339~346 (2018)
73. Rodger AJ, "Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIVpositive partner is using suppressive antiretroviral therapy", JAMA, 316, pp.171~181 (2016)
74. Del Romero J, "Natural conception in HIV-serodiscordant couples with the infected partner in suppressive antiretroviral therapy: A prospective cohort study", Medicine (Baltimore), 95, pp.e4398~ (2016)
75. Pilotto JH, "Maternal outcomes after HAART for the prevention of mother-to-child transmission in HIV-infected women in Brazil", Antivir Ther, 16, pp.349~356 (2011)
76. Becquet R, "Universal antiretroviral therapy among pregnant and postpartum HIV-infected women would improve maternal health and decrease postnatal HIV transmission", AIDS, 24, pp.1239~1241 (2010)
77. Becquet R, "Universal antiretroviral therapy for pregnant and breast-feeding HIV-1-infected women: towards the elimination of mother-to-child transmission of HIV-1 in resource-limited settings", Clin Infect Dis, 49, pp.1936~1945 (2009)
78. Townsend CL, "Low rates of motherto-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006", AIDS, 22, pp.973~981 (2008)
79. Tubiana R, "Factors associated with mother-to-child transmission of HIV-1 despite a maternal viral load <500 copies", ml at delivery: a case-control study nested in the French perinatal cohort (EPF-ANRS CO1), 2010, pp.50, 585~596
80. Mandelbrot L, "No perinatal HIV-1 transmission from women with effective antiretroviral therapy starting before conception", Clin Infect Dis, 61, pp.1715~1725 (2015)
81. Favarato G, "Migrant women living with HIV in Europe: are they facing inequalities in the prevention of mother-to-child-transmission of HIV?: The European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord", Eur J Public Health, 28, pp.55~60 (2018)
82. Anonymous, "ACOG committee opinion no. 751: Labor and delivery management of women with human immunodeficiency virus infection", Obstet Gynecol, 132, pp.e131~e137 (2018)
83. Alagaratnam J, "An observational study of initial HIV RNA decay following initiation of combination antiretroviral treatment during pregnancy", AIDS Res Ther, 17, pp.41~ (2020)
84. Read PJ, "When should HAART be initiated in pregnancy to achieve an undetectable HIV viral load by delivery?", AIDS, 26, pp.1095~1103 (2012)
85. Briand N, "Is intrapartum intravenous zidovudine for prevention of mother-to-child HIV-1 transmission still useful in the combination antiretroviral therapy era?", Clin Infect Dis, 57, pp.903~914 (2013)
86. Cotter AM, "Duration of membrane rupture and risk of perinatal transmission of HIV-1 in the era of combination antiretroviral therapy", Am J Obstet Gynecol, 207, pp.482.e1~482.e5 (2012)
87. Townsend CL, "Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000-2011", AIDS, 28, pp.1049~1057 (2014)
88. Yudin MH, "HIV and infant feeding in resource-rich settings: considering the clinical significance of a complicated dilemma", AIDS Care, 28, pp.1023~1026 (2016)
89. Wade NA, "Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus", N Engl J Med, 339, pp.1409~1414 (1998)
90. Nielsen-Saines K, "Three postpartum antiretroviral regimens to prevent intrapartum HIV infection", N Engl J Med, 366, pp.2368~2379 (2012)

관련 논문AI추천